Drugs / Karonudib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04077307 | Dec 2019 → Dec 2026 expected | leukemia | Thomas Helleday Foundation | Recruiting | No outcome recorded |
| Phase 1 | NCT03036228 | Jan 2017 → Dec 2024 | cancer | Thomas Helleday Foundation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Karonudib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04077307 ↗ |
| Known as | TH1579 | “To determine the safety and tolerability of Karonudib (TH1579) in escalating doses for the treatment of patients with advanced solid malignant tumours.” NCT03036228 ↗ |
| Action | Inhibit | “Karonudib is an oral inhibitor of MTH1 supplied as an oral solution and now as tablets.” NCT03036228 ↗ |
| Route | Oral | “Karonudib is an oral inhibitor of MTH1 supplied as an oral solution and now as tablets.” NCT03036228 ↗ |